fda drop us cig nicotin reduct return menthol
unifi agenda regulatori agenda fall publish rule relat
human servic hh hich seven relat tobacco notabl fda drop propos rule reduc nicotin level cig
non-addict level mention rule ban menthol cig also rule ban character flavor cigar
remain propos rule stage ith anoth extens deadlin march
 note new rule propos rule stage test standard batteri batteri manag system
battery-oper tobacco product e-cig clearli regulatori headw ind cig industri eas
time regulatori focu increasingli e-cig due tw issu higher youth access evali epidem e-cig
sale slow ed altria/bat report us cig volum e-cig stall cig volum improv pmta
deadlin may ill increas pressur e-cig
investor still nervou trump administr polici flavor e-cig ban remain unclear august altria stock
 trade pe bat stock trade pe current stock trade singl digit p/e core tobacco
busi remov equiti stake valu mo stock price regulatori headw ind eas margin us cig volum
improv think bat particular long ay go financi leverag ill magnifi equiti move
test standard batteri batteri manag system battery-oper tobacco product
rule ould propos establish product standard requir test standard batteri use electron nicotin deliveri
system end requir design protect includ batteri manag system end use batteri protect
hous replac batteri product standard ould protect safeti user battery-pow ere tobacco product
 ill help streamlin fda pre-market review process ultim reduc burden manufactur agenc
propos rule ould applic tobacco product includ non-us replac batteri ell product includ
user replac batteri unifi agenda regulatori agenda fall
tobacco relat item hhs/fda agenda fall
offic inform regulatori affair
tobacco relat item hhs/fda agenda spring
offic inform regulatori affair
tobacco relat item hhs/fda agenda
offic inform regulatori affair
tobacco relat item hhs/fda agenda prior
offic inform regulatori affair
fda rule-mak process multi-step process
bat offic manag budget
altria/bat report us cig volum e-cig stall
imperi brand plc new chairperson dividend stabil still grow ing ep support stock
bat pmi fda reportedli could announc e-cig flavor ban eek
british american tobacco plc meet ith cfo
inc long journey rebuild trust
japan tobacco guidanc low ere due eak rrp roll-out oct
global tobacco juul uk europ financi oct
sw edish match zyn off-set flavor cigar oe pt sek oct
european consum stapl vape epidem fallaci e-cig flavour ban oct
european consum stapl earn preview cut altria pt oct
imperi brand plc back ebit grow th compani sep
pm-mo ill merger back sep
european consum stapl dank vape youth tobacco survey forc fda hand sep
confer feedback tilray cover sep
confer feedback cover sep
confer feedback crono group cover sep
european consum stapl pm-mo chang exchang ratio aug
british american tobacco plc fx emerg major tailw ind aug
japan tobacco inc problem home aug
sw edish match zyn larg off-set cigar oe juli
replay confer call audio transcript confer call ith mr ill oodle kkb llp recent
evolut tobacco cannabi regul juli
global stapl pictur juli
inc iqo back track upgrad ow juli
 british american tobacco ill earli pmta deadlin deem product impact e-cig grow th juli
european consum stapl smoke signal second deriv us volum turn posit atermelon blueberri
imperi brand announc opportunist share buy-back juli
activist ex-regul suggest juul/clos tank get regul over-the-counter drug june
fda cig nicotin reduct rulemak move glacial pace jun
pm fda author market iqo us cig reduc risk author still aw ait may
smoke signal flavor ban ork evid us e-cig data feb
mentholet analys possibl implic menthol ban dec
smoke signal kick tyre ith juul sep
smoke signal juul disrupt come tobacco juli
imperi brand initi heat burn dow may
gaurav jain herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill directli
indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar hole part equiti research analyst base outsid us ho
registered/qualifi research analyst ith finra
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
research analyst employ outsid us affili barclay capit inc registered/qualifi research analyst
 ith finra non-u research analyst may associ person barclay capit inc hich finra member
therefor may subject finra rule restrict commun ith subject compani public appear
trade secur held research analyst account
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
materi conflict supervisori analyst review approv research report long posit common stock/adr
valuat methodolog set price target altria base price-to-earnings valuat last tw decad altria trade
averag fw multipl higher cigarett volum declin regulatori uncertainti manag attempt sell us
busi p/core tobacco ep expect pressur multipl near-term valu altria price-to-earnings add
addit valu per share juul crono get price target usd
risk may imped achiev barclay research valuat price target fda regul drastic
rate price target histori
prior intra-day chang may publish rate price target secur ere
histor stock price price target may adjust stock split dividend
materi conflict supervisori analyst review approv research report long posit common stock/adr
valuat methodolog consid british american tobacco valuat use three differ approach p/e-
base approach irr-bas approach part sotp set price target base approach
appli multipl ep result hich round
risk may imped achiev barclay research valuat price target regulatori agenda
fda ill domin headlin everi month like creat period heighten volatil altria aggress ith
iqo could lead signific up-front invest disrupt market share equilibrium damag market profit
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
